Business
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is
About this update from Scynexis, Inc.
[{"type":"text","content":"BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is continuing into Q4 with an additional 1,100 prescriptions reported in October.BREXAFEMME is now covered by commercial insurance plans representing more than 30% of commercially insured lives, exceeding internal expectations.Intravenous (IV) ibrexafungerp is ready to advance to the next stage of clinical development following successful Phase 1 trial evaluating safety and tolerability of liposomal IV formulation in healthy patients.Based on a $100 million cash balance at September 30 and operating plan, SCYNEXIS has a projected cash runway into 2023. JERSEY CITY, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended on September 30, 2021 and provided an update on recent clinical and corporate developments. “We are rapidly advancing every element of the BREXAFEMME commercial launch according to plan, and our efforts have been paying off,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “Physician and payer receptivity to the BREXAFEMME value proposition is extremely encouraging as we continue to see an impressive upward trajectory of prescriptions and expanded coverage during the initial stages of the launch. We also look forward to reporting top-line data from our Phase 3 CANDLE study by early Q2 of next year. Furthermore, we are thrilled to announce the successful completion of the Phase 1 study of our new IV formulation of ibrexafungerp which will enable us to further expand the potential range of indications in the hospital setting.” BREXAFEMME Commercial Update BREXAFEMME delivered $0.5 million in net sales in its first partial quarter of launch. IQVIA data showed 1,006 total prescriptions for BREXAFEMME in Q3 2021, with nearly 700 in September, which was in line with the company’s internal expectations for the first partial quarter of launch. There was a consistent week-over-week growth rate of prescriptions from early August to the end of the quarter, and a similar trajectory of growing positive momentum continuing into the fourth quarter...